MRE Biomarker Ctte: Difference between revisions
Jump to navigation
Jump to search
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
:Co-chairs: Richard L. Ehman, MD; Patricia Cole, PhD, MD | :Co-chairs: Richard L. Ehman, MD; Patricia Cole, PhD, MD | ||
* [https://docs.google.com/spreadsheets/d/e/2PACX-1vRXlDgOiADuCP3e9iHApSt4Z3zpel94OJN12IEQY8C4OT4u4LiiNnp9EWBP5FnCAgDL-YMe-m1NjasH/pubhtml?gid=1930876020&single=true Roster] | * [https://docs.google.com/spreadsheets/d/e/2PACX-1vRXlDgOiADuCP3e9iHApSt4Z3zpel94OJN12IEQY8C4OT4u4LiiNnp9EWBP5FnCAgDL-YMe-m1NjasH/pubhtml?gid=1930876020&single=true Roster] | ||
| Line 17: | Line 16: | ||
<br >Note: The last meeting of this group was held on December 20, 2021; notes are posted after they are approved by the MRE BC during the following t-con | <br >Note: The last meeting of this group was held on December 20, 2021; notes are posted after they are approved by the MRE BC during the following t-con | ||
*[[Media:2021_12-20_QIBA_MRE_BC_Call_Summary-FINAL.pdf|December 20, 2021]] | |||
*[[Media:2021_03-15_QIBA_MRE_BC_Call_Summary-FINAL.pdf|March 15, 2021]] | *[[Media:2021_03-15_QIBA_MRE_BC_Call_Summary-FINAL.pdf|March 15, 2021]] | ||
*[[Media:2020_01-23_QIBA_MRE_BC_Call_Summary-FINAL.pdf|January 23, 2020]] | *[[Media:2020_01-23_QIBA_MRE_BC_Call_Summary-FINAL.pdf|January 23, 2020]] | ||
'''''[[MRE BC Call Summaries Archive]]''''' | '''''[[MRE BC Call Summaries Archive]]''''' | ||
==MRE Profile Development== | ==MRE Profile Development== | ||
*[[Media:MRE-QIBAProfile-2023-11- | |||
*<td nowrap>[[Media:MRE-QIBAProfile-2023-11-07-CLINICALLY-FEASIBLE-maintenance.pdf|''MR Elastography of the Liver, Clinically Feasible Profile: Maintenance draft (November 7, 2023)'' <b>DOI:10.1148/QIBA/20231107</b>]]</td nowrap> | |||
*[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf|'''MR Elastography of the Liver, Clinically Feasible Profile (February 14, 2022)''']] | *[[Media:MRE-QIBAProfile-2022-02-14-TECHNICALLY-CONFIRMED.pdf|'''MR Elastography of the Liver, Clinically Feasible Profile (February 14, 2022)''']] | ||
*[[Media:MRE-QIBA_Profile-2021-06-22-CONSENSUS-maintenance.pdf | ''MR Elastography of the Liver Consensus Profile: Maintenance draft (June 22, 2021)'']] | *[[Media:MRE-QIBA_Profile-2021-06-22-CONSENSUS-maintenance.pdf | ''MR Elastography of the Liver Consensus Profile: Maintenance draft (June 22, 2021)'']] | ||
Latest revision as of 15:21, 11 July 2024
- Co-chairs: Richard L. Ehman, MD; Patricia Cole, PhD, MD
Project Snapshot
The MRE Biomarker Committee seeks to develop a quantitative Profile for MRE.
MRE Profile to be data-driven:
- focusing on the characterization of bias and precision in MRE measurement targets for achieving these measurements
- focusing on issues important to specific reproducibility
Meetings
Approved call summaries:
Note: The last meeting of this group was held on December 20, 2021; notes are posted after they are approved by the MRE BC during the following t-con
MRE Profile Development
- MR Elastography of the Liver, Clinically Feasible Profile: Maintenance draft (November 7, 2023) DOI:10.1148/QIBA/20231107
- MR Elastography of the Liver, Clinically Feasible Profile (February 14, 2022)
- MR Elastography of the Liver Consensus Profile: Maintenance draft (June 22, 2021)
- MR Elastography of the Liver Consensus Profile: Maintenance draft (June 6, 2019)
- MR Elastography of the Liver, Consensus Profile (May 2, 2018)
- MR Elastography of the Liver, Public Comment Profile (July 28, 2017)
- MR Elastography of the Liver, Initial Draft (July 6, 2017)